Table 4.
Odds ratio (OR) and 95% confidence interval (CI) of clinical status and AURKA rs2064863 genotypic frequencies in 312 HCC patients.
| Variable | Genotypic frequencies | |||
|---|---|---|---|---|
| TT (N=217) | GT+GG (N=95) | OR (95% CI) | p value | |
| Clinical Stage | ||||
| Stage I/II | 141 (65.0%) | 72 (75.8%) | 1.00 | P=0.061 |
| Stage III/IV | 76 (35.0%) | 23 (24.2%) | 0.593 (0.343-1.023) | |
| Tumor size | ||||
| ≤ T2 | 142 (65.4%) | 73 (76.8%) | 1.00 | P=0.047* |
| > T2 | 75 (34.6%) | 22 (23.2%) | 0.571 (0.328-0.992) | |
| Lymph node metastasis | ||||
| No | 209 (96.3%) | 93 (97.9%) | 1.00 | P=0.471 |
| Yes | 8 (3.7%) | 2 (2.1%) | 0.562 (0.117-2.697) | |
| Distant metastasis | ||||
| No | 205 (94.5%) | 92 (96.8%) | 1.00 | P=0.374 |
| Yes | 12 (5.5%) | 3 (3.2%) | 0.557 (0.154-2.021) | |
| Vascular invasion | ||||
| No | 176 (81.1%) | 82 (86.3%) | 1.00 | P=0.265 |
| Yes | 41 (18.9%) | 13 (13.7%) | 0.681 (0.346-1.339) | |
| Child-Pugh grade | ||||
| A | 161 (74.2%) | 81 (85.3%) | 1.00 | P=0.033* |
| B or C | 56 (25.8%) | 14 (14.7%) | 0.497 (0.261-0.946) | |
| HBsAg | ||||
| Negative | 117 (53.9%) | 58 (61.1%) | 1.00 | P=0.193 |
| Positive | 100 (46.1%) | 37 (38.9%) | 0.793 (0.559-1.125) | |
| Anti-HCV | ||||
| Negative | 119 (54.8%) | 45 (47.4%) | 1.00 | P=0.039* |
| Positive | 98 (45.2%) | 50 (52.6%) | 1.441 (1.019-2.038) | |
| Liver cirrhosis | ||||
| Negative | 38 (17.5%) | 14 (14.7%) | 1.00 | P=0.546 |
| Positive | 179 (82.5%) | 81 (85.3%) | 1.228 (0.631-2.392) | |
The ORs with analyzed by their 95% CIs were estimated by logistic regression models.
> T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)
* p value < 0.05 as statistically significant.